Evidence map›Paper›PMID 31041128›Full record

ReviewNeurology. Clinical practice2019

Role of CYP2C19 alleles in the management of recurrent ischemic stroke.

Michael J Lyerly, Kelly Bartlett, Karen C Albright

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology. Clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michael J LyerlyDepartment of Neurology (M.J.L.), University of Alabama at Birmingham; Center for Global Health and Translational Science (K.B., K.C.A.), SUNY Upstate Medical University; and Department of Neurology (K.C.A.), SUNY Upstate Medical University, Syracuse, NY.
Kelly BartlettDepartment of Neurology (M.J.L.), University of Alabama at Birmingham; Center for Global Health and Translational Science (K.B., K.C.A.), SUNY Upstate Medical University; and Department of Neurology (K.C.A.), SUNY Upstate Medical University, Syracuse, NY.
Karen C AlbrightDepartment of Neurology (M.J.L.), University of Alabama at Birmingham; Center for Global Health and Translational Science (K.B., K.C.A.), SUNY Upstate Medical University; and Department of Neurology (K.C.A.), SUNY Upstate Medical University, Syracuse, NY.
University of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewCYP2C19 is the primary enzyme involved in the activation of clopidogrel, an antiplatelet agent used for secondary stroke prevention. An individual's RECENT

findingsThree ischemic stroke cases were treated with clopidogrel. Despite confirming adequate drug exposure, medication adherence, and ruling out drug-drug interactions, all had recurrent ischemic stroke. Each case had a SUMMARY: These cases illustrate the importance of a thoughtful approach to secondary stroke prevention and demonstrate the utility of pharmacogenomic testing in clopidogrel hyporesponders. Recognition of the importance of

Identifiers

PMID31041128
PMCPMC6461431
OpenAlexW2906568249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.